A detailed history of Callahan Advisors, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Callahan Advisors, LLC holds 4,119 shares of GILD stock, worth $362,801. This represents 0.03% of its overall portfolio holdings.

Number of Shares
4,119
Previous 3,111 32.4%
Holding current value
$362,801
Previous $227,000 24.23%
% of portfolio
0.03%
Previous 0.02%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 29, 2024

BUY
$63.15 - $72.88 $63,655 - $73,463
1,008 Added 32.4%
4,119 $282,000
Q1 2024

Apr 24, 2024

BUY
$71.58 - $87.29 $572 - $698
8 Added 0.26%
3,111 $227,000
Q4 2023

Jan 24, 2024

BUY
$73.27 - $83.09 $439 - $498
6 Added 0.19%
3,103 $251,000
Q3 2023

Oct 23, 2023

BUY
$73.94 - $80.67 $517 - $564
7 Added 0.23%
3,097 $232,000
Q2 2023

Jul 31, 2023

SELL
$76.01 - $86.7 $37,472 - $42,743
-493 Reduced 13.76%
3,090 $238,000
Q1 2023

Apr 28, 2023

SELL
$77.31 - $88.08 $11,132 - $12,683
-144 Reduced 3.86%
3,583 $297,000
Q4 2022

Feb 03, 2023

BUY
$62.32 - $89.47 $1,682 - $2,415
27 Added 0.73%
3,727 $319,000
Q3 2022

Oct 27, 2022

BUY
$59.54 - $68.01 $535 - $612
9 Added 0.24%
3,700 $228,000
Q2 2022

Jul 29, 2022

BUY
$57.72 - $65.01 $519 - $585
9 Added 0.24%
3,691 $228,000
Q1 2022

Apr 27, 2022

BUY
$57.92 - $72.58 $213,261 - $267,239
3,682 New
3,682 $219,000
Q4 2021

Feb 08, 2022

SELL
$64.88 - $73.64 $185,881 - $210,978
-2,865 Closed
0 $0
Q3 2021

Nov 03, 2021

BUY
$67.69 - $73.03 $193,931 - $209,230
2,865 New
2,865 $200,000
Q1 2021

Apr 21, 2021

SELL
$60.0 - $68.46 $230,580 - $263,091
-3,843 Closed
0 $0
Q4 2020

Jan 20, 2021

BUY
$56.65 - $64.55 $11,726 - $13,361
207 Added 5.69%
3,843 $224,000
Q3 2020

Oct 26, 2020

SELL
$62.1 - $78.08 $38,998 - $49,034
-628 Reduced 14.73%
3,636 $230,000
Q2 2020

Jul 17, 2020

SELL
$72.34 - $84.0 $25,970 - $30,156
-359 Reduced 7.77%
4,264 $328,000
Q1 2020

Apr 06, 2020

SELL
$62.63 - $80.22 $37,264 - $47,730
-595 Reduced 11.4%
4,623 $346,000
Q4 2019

Jan 21, 2020

SELL
$61.62 - $67.78 $30,440 - $33,483
-494 Reduced 8.65%
5,218 $339,000
Q3 2019

Oct 21, 2019

SELL
$62.51 - $69.0 $58,384 - $64,446
-934 Reduced 14.05%
5,712 $362,000
Q2 2019

Jul 17, 2019

SELL
$61.87 - $69.38 $166,677 - $186,909
-2,694 Reduced 28.84%
6,646 $449,000
Q1 2019

Apr 22, 2019

SELL
$62.53 - $70.05 $1.02 Million - $1.14 Million
-16,244 Reduced 63.49%
9,340 $607,000
Q4 2018

Jan 24, 2019

SELL
$60.54 - $79.0 $175,263 - $228,705
-2,895 Reduced 10.17%
25,584 $1.6 Million
Q3 2018

Oct 15, 2018

SELL
$71.28 - $78.92 $3.81 Million - $4.22 Million
-53,497 Reduced 65.26%
28,479 $2.2 Million
Q2 2018

Jul 19, 2018

SELL
$64.88 - $75.68 $263,737 - $307,639
-4,065 Reduced 4.72%
81,976 $5.81 Million
Q1 2018

Apr 30, 2018

BUY
$72.84 - $88.8 $174,306 - $212,498
2,393 Added 2.86%
86,041 $6.49 Million
Q4 2017

Jan 31, 2018

SELL
$71.15 - $83.52 $455,929 - $535,196
-6,408 Reduced 7.12%
83,648 $5.99 Million
Q3 2017

Oct 26, 2017

BUY
$72.11 - $85.47 $6.49 Million - $7.7 Million
90,056
90,056 $7.3 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $110B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Callahan Advisors, LLC Portfolio

Follow Callahan Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Callahan Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Callahan Advisors, LLC with notifications on news.